Clinical Trials · NCT00696644

A Study for Teriparatide in Severe Osteoporosis

Phase
N/A
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
794
Start date
Jun 2008
Locations
1 site, Italy
Primary endpoint
Incidence of any osteoporotic fractures in the first 24 months from the initiation of anabolic medication.
View Teriparatide compound reference